for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Cumberland Pharmaceuticals, Inc.

CPIX.O

Latest Trade

3.02USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

2.94

 - 

5.80

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
3.02
Open
--
Volume
--
3M AVG Volume
0.38
Today's High
--
Today's Low
--
52 Week High
5.80
52 Week Low
2.94
Shares Out (MIL)
15.14
Market Cap (MIL)
45.72
Forward P/E
--
Dividend (Yield %)
--

Next Event

Q3 2020 Cumberland Pharmaceuticals Inc Earnings Release

Latest Developments

More

Cumberland Enters Third Amendment To Revolving Credit Note, Fourth Amendment To Revolving Credit Loan Agreement

Cumberland Pharmaceuticals Reports Q2 Loss Per Share Of $0.06

Cumberland Posts Q1 Adjusted EPS Of $0.01

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Cumberland Pharmaceuticals, Inc.

Cumberland Pharmaceuticals Inc. (Cumberland) is a specialty pharmaceutical company. The Company is focused on the acquisition, development and commercialization of branded prescription products. The Company operates through specialty pharmaceutical products segment. The Company's product portfolio includes Acetadote (acetylcysteine) Injection for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) Injection for the treatment of pain and fever; Kristalose (lactulose) for Oral Solution for the treatment of chronic and acute constipation; Omeclamox-Pak, (omeprazole, clarithromycin, amoxicillin) for the treatment of Helicobacter pylori (H. pylori) infection and related duodenal ulcer disease; Vaprisol (conivaptan) Injection to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Hepatoren (ifetroban) Injection, and Boxaban (ifetroban) oral capsules for the treatment of patients with aspirin-exacerbated respiratory disease (AERD).

Industry

Biotechnology & Drugs

Contact Info

2525 W End Ave Ste 950

NASHVILLE, TN

37203-1608

United States

+1.615.2550068

http://www.cumberlandpharma.com/

Executive Leadership

A. J. Kazimi

Chairman of the Board, Chief Executive Officer

Michael P. Bonner

Senior Director Finance and Accounting and Chief Financial Officer

Martin E. Cearnal

Executive Vice President, Chief Commercial Officer, Director

Leo B. Pavliv

Executive Vice President - Operations, Chief Development Officer

James L. Herman

Vice President - National Accounts, Chief Compliance Officer

Key Stats

2.50 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (USD)

2018

-0.030

2019

0.320

2020(E)

0.090
Price To Earnings (TTM)
--
Price To Sales (TTM)
1.09
Price To Book (MRQ)
0.95
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
35.07
LT Debt To Equity (MRQ)
35.07
Return on Investment (TTM)
-8.10
Return on Equity (TTM)
-6.34

Latest News

Latest News

BRIEF-Cumberland Posts Q1 Adjusted EPS Of $0.01

* CUMBERLAND PHARMACEUTICALS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS & COMPANY UPDATE

BRIEF-To Help Prepare For The Covid-19 Patient Surge Cumberland Pharmaceuticals Expands Availability Of Vaprisol® To Treat Hyponatremia In Critical Care Units

* TO HELP PREPARE FOR THE COVID-19 PATIENT SURGE CUMBERLAND PHARMACEUTICALS EXPANDS AVAILABILITY OF VAPRISOL® TO TREAT HYPONATREMIA IN CRITICAL CARE UNITS Source text for Eikon: Further company coverage:

BRIEF-Cumberland To Expand Availability Of Caldolor For High Fever Associated With Coronavirus

* CUMBERLAND PHARMACEUTICALS ANNOUNCES INITIATIVE TO EXPAND AVAILABILITY OF CALDOLOR® TO HELP TREAT HIGH FEVERS ASSOCIATED WITH CORONAVIRUS INFECTIONS

BRIEF-Cumberland Pharmaceuticals Inc - Initiative Designed To Help Address Potential Antibiotic Shortages

* CUMBERLAND PHARMACEUTICALS ANNOUNCES INITIATIVE TO EXPAND AVAILABILITY OF VIBATIV® TO TREAT HOSPITAL-ACQUIRED & VENTILATOR-ASSOCIATED PNEUMONIA RESULTING FROM CORONAVIRUS INFECTIONS

BRIEF-Cumberland Pharmaceuticals Reports 17% Revenue Growth For The Full Year 2019

* CUMBERLAND PHARMACEUTICALS REPORTS 17% REVENUE GROWTH FOR THE FULL YEAR 2019

BRIEF-Cumberland Pharmaceuticals Reports Q1 Adjusted Loss Per Share $0.09

* CUMBERLAND PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Cumberland Pharmaceuticals Expands Into Oncology Support

* CUMBERLAND PHARMACEUTICALS EXPANDS INTO ONCOLOGY SUPPORT Source text for Eikon: Further company coverage:

BRIEF-Cumberland Pharmaceuticals- Entered Agreement With Gastro-Entero Logic To Acquire Assets Associated With Omeclamox((Reg))-Pak

* CUMBERLAND PHARMACEUTICALS-ON MARCH 13, ENTERED AGREEMENT WITH GASTRO-ENTERO LOGIC, LLC TO ACQUIRE ASSETS ASSOCIATED WITH OMECLAMOX -PAK

BRIEF-Cumberland Pharma Q4 Adjusted Earnings Per Share $0.03

* CUMBERLAND PHARMACEUTICALS REPORTS 25% REVENUE GROWTH FOR THE FULL YEAR 2017

BRIEF-Cumberland Pharma Says Data Demonstrates Amifostine Reduces Gastro-Intestinal Toxicity For Multiple Myeloma Patients

* CUMBERLAND PHARMACEUTICALS INC - NEWLY PUBLISHED DATA DEMONSTRATES AMIFOSTINE REDUCES GASTRO-INTESTINAL TOXICITY FOR MULTIPLE MYELOMA PATIENTS Source text for Eikon: Further company coverage:

BRIEF-Cumberland Pharmaceuticals Inc files for mixed shelf of up to $100 million

* Cumberland Pharmaceuticals Inc files for mixed shelf of up to $100 million Source text: (http://bit.ly/2jazuqV) Further company coverage:

BRIEF-Cumberland Pharmaceutical reports Q3 loss per share $0.05

* Cumberland Pharmaceutical reports 27% revenue growth in the third quarter

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up